Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Highlights the limitation of current performance measures that track medication administration post-MI without assessing optimal dosing, particularly for statins.
] Performance measures track whether or not evidence-based medications are administered after MI. However, they do not assess whether or not the dose is optimal. The dose is an important issue for statins, because their efficacy to prevent recurrent MI and death after the initial event has been shown to be greater at higher doses.
No takes yet. Share an insight, caveat, or question.
Véronique L. Roger (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: